EthOss® Regeneration Ltd has further expanded its reach across the Middle East with the news that the company has received regulatory approval for its primary product, EthOss®, to be sold in Jordan.
The approval from the Jordan Food and Drug Administration, the governing body for medical products in the country, means that EthOss® is now freely available to dentists and patients across Jordan, a market of over 10 million people.
The announcement follows two large presentations in Amman from Dr Peter Fairbairn, internationally renowned dentist and Clinical Director of EthOss® Regeneration Ltd.
These presentations were delivered to a senior delegation at the Jordanian Royal Medical Services Military Hospital, part of the King Hussein Medical Center, and at an official “launch” event for EthOss at the Four Seasons Hotel in Amman, the capital city of Jordan – with more than 500 delegates in attendance over the course of the two meetings.
In conjunction with the approval, EthOss® Regeneration has also signed up an exclusive distribution deal for the market with Plus+ Dental Supplies.
EthOss® has proved hugely popular with dentists across the world due to a number of benefits to both end-user and patient.
The unique composition of EthOss®, which has a built-in cell-occlusive barrier, removing the need for a separate collagen membrane, provides a highly stable graft and typically produces 50 per cent new bone after 12 weeks.
EthOss® is a bi-phasic synthetic material made from a mixture of beta tricalcium phosphate and calcium sulphate and is completely free from animal or human content.
The built-in membrane function prevents soft tissue ingress and helps to dramatically speed up healing times, by allowing the periosteum (and the related blood supply) direct contact with the graft site. This means surgical procedures can be completed much more quickly and reliably, benefitting both patient and dentist.
The multi award-winning British company brought EthOss® to the Middle East, North Africa and South Asia (MENASA) region for the first time at the AEEDC Dubai congress in February this year and recently received approval to sell the product in the United Arab Emirates.
Dr Peter Fairbairn, Clinical Director of EthOss® Regeneration Ltd, said: “There is a real desire in the Middle Eastern dental market for innovative bone grafting solutions and EthOss® is answering that demand.
“The two presentations I delivered in Amman were really well received. There was a clear recognition that EthOss® is responding to the needs of both dentists and patients on the design of the product, the speed of healing times, and not using animal or human content.
“With regulatory approval now secured in Jordan, we can begin to help dentists put this shift in bone-grafting technique into practice right across the country and we look forward to working with our partners to achieve that.”